{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:30:30Z","timestamp":1790512230826,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.urolonc.2007.05.011","type":"journal-article","created":{"date-parts":[[2007,9,8]],"date-time":"2007-09-08T07:19:13Z","timestamp":1189235953000},"page":"433-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Targeted therapies in bladder cancer\u2014an update"],"prefix":"10.1016","volume":"25","author":[{"given":"Peter C.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.N.","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2007.05.011_bib1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib2","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib3","article-title":"Distinctive expression patterns of ErbB family receptors signify an aggressive variant of bladder cancer","author":"Kassouf","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1046\/j.1464-410x.1999.00914.x","article-title":"Epidermal growth factor receptor expression: Predictive value for the outcome after cystectomy for bladder cancer?","volume":"83","author":"Sriplakich","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2007.05.011_bib5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(01)67604-3","article-title":"Long-term outcome related to epidermal growth factor receptor status in bladder cancer","volume":"153","author":"Mellon","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib6","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1158\/0008-5472.CAN-05-1536","article-title":"Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells","volume":"65","author":"Kassouf","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2007.05.011_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.juro.2006.03.072","article-title":"Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer","volume":"176","author":"Kassouf","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled, multicenter study: IRESSA Survival Evaluation in Lung Cancer","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2007.05.011_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib10","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/jco.2004.22.90140.7010","article-title":"Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)","volume":"22","author":"Gatzemeier","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib11","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: A Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2005.23.16_suppl.1","article-title":"Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer","volume":"23","author":"Moore","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib15","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer","volume":"24","author":"Hirsch","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2007.05.011_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib18","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-06-0407","article-title":"Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy","volume":"12","author":"Blehm","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2007.05.011_bib19","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1073\/pnas.0510284103","article-title":"Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors","volume":"103","author":"Ji","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2007.05.011_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.ju.0000108845.91485.20","article-title":"Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy","volume":"171","author":"Slaton","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/1535-7163.MCT-06-0513","article-title":"Molecular correlates of gefitinib responsiveness in human bladder cancer cells","volume":"6","author":"Shrader","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2007.05.011_bib22","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","article-title":"Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm","volume":"21","author":"Burstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib23","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib24","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2007.05.011_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-5347(01)66653-9","article-title":"C-erbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value","volume":"155","author":"Mellon","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ijc.10731","article-title":"HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications","volume":"102","author":"Kruger","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2007.05.011_bib27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cncr.10808","article-title":"Does HER2\/neu expression provide prognostic information in patients with advanced urothelial carcinoma?","volume":"95","author":"Gandour-Edwards","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2007.05.011_bib28","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/jco.2005.23.16_suppl.4507","article-title":"Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center Phase II NCI trial","volume":"23","author":"Hussain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.2004.04814.x","article-title":"Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma","volume":"124","author":"Paterson","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib30","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","article-title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","volume":"107","author":"Trudel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.urolonc.2007.05.011_bib31","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","article-title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","volume":"105","author":"Trudel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.urolonc.2007.05.011_bib32","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle-invasive urothelial bladder carcinomas","volume":"24","author":"Hernandez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib33","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/sj.onc.1204110","article-title":"Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma","volume":"20","author":"Sibley","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2007.05.011_bib34","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib35","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma","volume":"24","author":"Jebar","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2007.05.011_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.yexcr.2004.11.012","article-title":"Cell responses to FGFR3 signaling: Growth, differentiation and apoptosis","volume":"304","author":"L\u2019Hote","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.urolonc.2007.05.011_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.459.11.2","article-title":"Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth","volume":"11","author":"Gomez-Roman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2007.05.011_bib38","first-page":"1265","article-title":"The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate","volume":"61","author":"van Rhijn","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2007.05.011_bib39","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/carcin\/bgi290","article-title":"Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b","volume":"27","author":"Bernard-Pierrot","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2007.05.011_bib40","first-page":"975","article-title":"Down-regulation of FGFR3 illustrates the potential of FGFR3 targeted therapy in bladder cancer","volume":"2006","author":"Tomlinson","year":"2006","journal-title":"AACR Meeting"},{"key":"10.1016\/j.urolonc.2007.05.011_bib41","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib42","first-page":"S6","article-title":"A randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100)","volume":"94","author":"Miller","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.urolonc.2007.05.011_bib43","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.05.011_bib45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.urolonc.2007.05.011_bib46","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1001\/jama.295.21.2537","article-title":"A new strategy in the war on renal cell cancer: Hitting multiple targets with limited collateral damage","volume":"295","author":"Pasche","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2007.05.011_bib47","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2007.05.011_bib48","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143907001445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143907001445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:53:39Z","timestamp":1761040419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143907001445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1078143907001445"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2007.05.011","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapies in bladder cancer\u2014an update","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2007.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}